Comparative Evaluation of Anorganic Bovine Bone Matrix (ABBM) with or without Platelet Rich Fibrin intreatment of Intrabony Defects:A Randomized Controlled Trial

Authors

  • Deepali Singhal
  • Shweta Bali
  • Priyanka Aggarwal
  • Aruna Nautiyal
  • Kirti Pal

DOI:

https://doi.org/10.47750/pnr.2022.13.S06.224

Keywords:

Anaoraganic bovine bone matrix, Blood concentrates, clinical attachment level, growth factors, intrabony defects, platelet rich fibrin, wound healing index, xenograft.

Abstract

Background: Risk of alveolar bone loss & tooth loss increases with the presence of intrabony defects. Anoraganic bovine bone mineral (ABBM) is being used in treatment of intrabony defects.Platelet-rich fibrin (PRF) is an autologous concentrate thathas an important role inpromoting soft and hard tissue healing.This study was done to compare and evaluate the healing of intra-bony defects treated with a combination of ABBM-PRF or ABBM alone.
Method: Twelve patients (24 sites) with intrabony defects were selected and divided randomly in 2 groups. Subjects in Group A (Control group ) were treated with ABBM alone & subjects in Group B (test Group ) were treated with ABBM + PRF.Clinical parameters such as PPD(Probing pocket depth), CAL(Clinical attachment level), PI(plaque index), GI(gingival index), WHI(Wound healing index), VBL(Vertical Bone Level)& DD(Defect depth) at baseline, 3 and 6 months using acrylic stent.
Result: Significant gain in PPD& CAL( 3.92± 0.67 to 2.00± 0.74) was seen from baseline to 6 months in test group ( p<0.001) as compared to control group.Also vertical bone level wasincreased in test groupi.e from 3.50 ± 0.52 to 3.00± 0.43 (p<0.001) post – operative when compared to control group at 6 months.
Conclusion: The addition of PRF to ABBM can augment regeneration and can lead to enhancement of CAL gain.

Downloads

Published

2022-10-12

Issue

Section

Articles

How to Cite

Comparative Evaluation of Anorganic Bovine Bone Matrix (ABBM) with or without Platelet Rich Fibrin intreatment of Intrabony Defects:A Randomized Controlled Trial. (2022). Journal of Pharmaceutical Negative Results, 1703-1710. https://doi.org/10.47750/pnr.2022.13.S06.224